193
Views
10
CrossRef citations to date
0
Altmetric
Mental Health

Depression symptoms and quality of life among individuals with aspirin-exacerbated respiratory disease

, PhD, , MA, , MA, , MA, , BA, , MD, , MD, PhD & , MD, MSc show all
Pages 731-738 | Received 05 May 2018, Accepted 14 Jun 2018, Published online: 16 Oct 2018

References

  • Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012;18:716–725.
  • Laidlaw TM, Boyce JA. Aspirin-exacerbated respiratory disease-new prime suspects. N Engl J Med 2016;374:484–488.
  • Chang JE, White A, Simon RA, Stevenson DD. Aspirin-exacerbated respiratory disease: burden of disease. Allergy Asthma Proc. 2012;33:117–121.
  • Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol 2006;118:773–786.
  • Kennedy JL, Stoner AN, Borish L. Aspirin-exacerbated respiratory disease: prevalence, diagnosis, treatment, and considerations for the future. Am J Rhinol Allerg 2016;30:407.
  • Szczeklik A, Niżankowska E, Duplaga M, Of OB. Natural history of aspirin-induced asthma. AIANE investigators. European Network on Aspirin-Induced Asthma. Eur Respir J 2000;16:432–436.
  • Rajan JP, Wineinger NE, Stevenson DD, White AA. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature. J Allergy Clin Immunol 2015;135:676–681. e1.
  • Mahdavinia M, Benhammuda M, Codispoti CD, Tobin MC, Losavio PS, Mehta A, Jeffe JS, et al. African American patients with chronic rhinosinusitis have a distinct phenotype of polyposis associated with increased asthma hospitalization. J Allergy Clin Immunol Pract 2016;4:658–664. e1.
  • Lee RU, Stevenson DD. Aspirin-exacerbated respiratory disease: evaluation and management. Allergy Asthma Immunol Res 2011;3:3–10.
  • Hope AP, Woessner KA, Simon RA, Stevenson DD. Rational approach to aspirin dosing during oral challenges and desensitization of patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2009;123:406–410.
  • Berges-Gimeno MP, Simon RA, Stevenson DD. Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2003;90:338–341.
  • Berges-Gimeno MP, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2003;111:180–186.
  • Świerczyńska-Krępa M, Sanak M, Bochenek G, Stręk P, Ćmiel A, Gielicz A, Plutecka H, et al. Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study. J Allergy Clin Immunol 2014;134:883–890.
  • Laidlaw TM. How patient experiences should change our approach to treating patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract 2015;3:719–720.
  • Ta V, White AA. Survey-defined patient experiences with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract 2015;3:711–718.
  • Jerschow E, Edin ML, Pelletier T, Abuzeid WM, Akbar NA, Gibber M, Fried M, et al. Plasma 15-hydroxyeicosatetraenoic acid predicts treatment outcomes in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract 2017;5:998–1007. e2.
  • Wenzel S. Severe asthma: from characteristics to phenotypes to endotypes. Clin Exp Allergy 2012;42:650–658.
  • Gudziol V, Michel M, Sonnefeld C, Koschel D, Hummel T. Olfaction and sinonasal symptoms in patients with CRSwNP and AERD and without AERD: a cross-sectional and longitudinal study. Eur Arch Otorhinolaryngol 2017;274:1487–1493.
  • Goodwin RD, Jacobi F, Thefeld W. Mental disorders and asthma in the community. Arch Gen Psychiatry 2003;60:1125–1130.
  • Lu Y, Mak KK, Van Bever HP, Ng TP, Mak A, Ho RCM. Prevalence of anxiety and depressive symptoms in adolescents with asthma: a meta-analysis and meta-regression. Pediatr Allergy Immunol 2012;23:707–715.
  • Trojan TD, Khan DA, Defina LF, Akpotaire O, Goodwin RD, Brown ES. Asthma and depression: the Cooper Center Longitudinal Study. Ann Allergy Asthma Immunol 2014;112:432–436.
  • Goodwin RD, Scheckner B, Pena L, Feldman JM, Taha F, Lipsitz JD. A 10-year prospective study of respiratory disease and depression and anxiety in adulthood. Ann Allergy Asthma Immunol 2014;113:565–570.
  • Feldman JM, Siddique MI, Morales E, Kaminski B, Lu SE, Lehrer PM. Psychiatric disorders and asthma outcomes among high-risk inner-city patients. Psychosom Med 2005;67:989–996.
  • Brown ES, Khan DA, Mahadi S. Psychiatric diagnoses in inner city outpatients with moderate to severe asthma. Int J Psychiatry Med 2000;30:319–327.
  • Erdogan T, Karakaya G, Kalyoncu A. Comorbid diseases in aspirin-exacerbated respiratory disease, and asthma. Allergol Immunopathol 2015;43:442–448.
  • Labor M, Labor S, Juric I, Fijacko V, Grle SP, Plavec D. Mood disorders in adult asthma phenotypes. J Asthma 2018;55:57–65.
  • Koinis-Mitchell D, Kopel SJ, Boergers J, McQuaid EL, Esteban CA, Seifer R, Fritz GK, et al. Good sleep health in urban children with asthma: a risk and resilience approach. J Pediatr Psychol 2015;40:888–903.
  • Koinis-Mitchell D, McQuaid EL, Jandasek B, Kopel SJ, Seifer R, Klein RB, Potter C, et al. Identifying individual, cultural and asthma-related risk and protective factors associated with resilient asthma outcomes in urban children and families. J Pediatr Psychol 2012;37:424–437.
  • Feldman JM, Matte L, Interian A, Lehrer PM, Lu S-E, Scheckner B, Steinberg DM, et al. Psychological treatment of comorbid asthma and panic disorder in Latino adults: results from a randomized controlled trial. Behav Res Ther 2016;87:142–154.
  • Miller M, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardization of spirometry, 1994 update. American thoracic society. Am J Respir Crit Care Med 1995;152:1107–1136.
  • Beck AT, Steer RA, Brown GK. Beck Depression Inventory-II. San Antonio, TX: The Psychological Corporation; 1996.
  • Dozois DJ, Dobson KS, Ahnberg JL. A psychometric evaluation of the Beck Depression Inventory–II. Psychol Assess 1998;10:83.
  • Wiebe JS, Penley JA. A psychometric comparison of the Beck Depression Inventory-II in English and Spanish. Psychol Assess 2005;17:481
  • Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999;14:902–907.
  • Sanjuás C, Alonso J, Ferrer M, Curull V, Broquetas JM, Antó JM. Adaptation of the Asthma Quality of Life Questionnaire to a second language preserves its critical properties: the Spanish version. J Clin Epidemiol 2001;54:182–189.
  • NHLBI. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MA 2007. Contract No.: 08-4051.
  • Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale, NJ: Law-rence Erlbaum Associates. Inc, Publishers; 1988.
  • SPSS I. IBM SPSS statistics for Windows, version 24.0. New York: IBM Corp; 2015.
  • McQuaid EL, Kopel SJ, Nassau JH. Behavioral adjustment in children with asthma: a meta-analysis. J Dev Behav Pediatr 2001;22:430–439.
  • Mrazek D, Anderson I, Strunk R. Disturbed emotional development of severely asthmatic preschool children. J Child Psychol Psychiatry 1985;26:81–94.
  • Steinke JW, Wilson JM. Aspirin-exacerbated respiratory disease: pathophysiological insights and clinical advances. J Asthma Allergy 2016;9:37–43.
  • Berges-Gimeno MP, Simon RA, Stevenson DD. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2002;89:474–478.
  • Bochenek G, Stachura T, Szafraniec K, Plutecka H, Sanak M, Nizankowska-Mogilnicka E, Sladek K. Diagnostic accuracy of urinary LTE4 measurement to predict aspirin-exacerbated respiratory disease in patients with asthma. J Allergy Clin Immunol Pract 2018;6:528–535.
  • Perona AA, García-Sáiz M, Álvarez ES. Psychiatric disorders and montelukast in children: a disproportionality analysis of the VigiBase(®). Drug Saf 2016;39:69–78.
  • Calapai G, Casciaro M, Miroddi M, Calapai F, Navarra M, Gangemi S. Montelukast-induced adverse drug reactions: a review of case reports in the literature. Pharmacology 2014;94:60–70.
  • Schumock GT, Lee TA, Joo MJ, Valuck RJ, Stayner LT, Gibbons RD. Association between leukotriene-modifying agents and suicide: what is the evidence? Drug Saf 2011;34:533–544.
  • Gelosa P, Colazzo F, Tremoli E, Sironi L, Castiglioni L. Cysteinyl leukotrienes as potential pharmacological targets for cerebral diseases. Mediators Inflamm 2017;2017:3454212.
  • Ghosh A, Chen F, Thakur A, Hong H. Cysteinyl leukotrienes and their receptors: emerging therapeutic targets in central nervous system disorders. CNS Neurosci Ther 2016;22:943–951.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.